Update on CHANGE-MS Clinical Trial Results for GNbAC1

Is the cause of MS within us?

By Daniel Kantor, MD, FAAN, FANA

At the recent annual meeting of the Consortium of Multiple Sclerosis Centers in Nashville, researchers presented an exciting 48-week update of the phase 2 clinical trial assessing the pHERV-W Env antagonist, GNbAC1, for efficacy in treating patients with MS (CHANGE-MS). The compound being studied, GNbAC1, targets the envelope protein (Env) of the human endogenous multiple sclerosis-associated retro-virus (HERV-W/MSRV), thought to play a critical role in the pathophysiology of multiple sclerosis (MS).

Potential Breakthrough Relevance: Addressing the Cause of MS

Clinical trials of GNbAC1 also test a new hypothesis for the actual cause of MS.\(^1\)\(^-\)\(^4\) The antigen for GNbAC1 is an Env protein found on monocytes and microglia. The Env protein is encoded for by a type of DNA element termed a pathogenic human endogenous retrovirus (pHERV). These represent ancient viral DNA incorporated into the human genome millions of years ago. Approximately 8% of the human genome consists of such viral DNA incorporations.

Efficacy of GNbAC1 in MS suggests that the initial viral trigger for MS is not simply an early childhood viral exposure that triggers MS in a genetically susceptible individual. These results suggest instead that the initial viral basis of MS is some of the ancient viral DNA in our genome lying dormant within us that is derepressed by environmental viruses (eg, Epstein-Barr virus).\(^5\)

CHANGE-MS Results

The 24-week results of CHANGE-MS showed a statistical trend favoring remyelination at the highest dose tested (18 mg/kg monthly).\(^6\) All patients who had not dropped out of the 24-week placebo-controlled trial (n = 247) continued on active treatment. Patients who had been treated with placebo were randomized to doses of 6 mg/kg, 12 mg/kg, or 18 mg/kg GNbAC1 given monthly.

Benefit on Slowing Down Brain Atrophy

After another 24 weeks (week 48), analysis compared patients who had been continuously treated with one of the escalating doses of GNbAC1 to the control group that had been treated with placebo for the first 24 weeks, then by 6 mg/kg, 12 mg/kg, or 18 mg/kg monthly for an additional 24 weeks). Patients who had been treated continuously with 18 mg/kg of GNbAC1 had brain imaging evidence for benefit on key markers of neurodegeneration (Table), linked to disease progression:

- Thalamic, cerebral cortex, and whole brain volumes
- T1 hypointensities (commonly termed black holes)
- MTR (magnetization transfer ratio)

The rate of atrophy (volume loss) is accelerated in MS; continuous treatment with GNbAC1 18 mg/kg, administered monthly, slowed the rate of atrophy in the thalamus and cerebral cortex. Although differences in whole brain volume loss were not statistically significant, an inflection point in the rate of volume loss was seen at the point where patients transitioned from placebo to active treatment.

### TABLE. KEY MARKERS OF NEURODEGENERATION AFTER TREATMENT WITH GNbAC1

<table>
<thead>
<tr>
<th>Region</th>
<th>Group</th>
<th>Median % reduction week 48</th>
<th>Relative reduction atrophy</th>
<th>Spearman coefficient dose-effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Thalamus</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control mg/kg</td>
<td>-1.27</td>
<td>72%</td>
<td>P = .014</td>
<td></td>
</tr>
<tr>
<td>Cerebral cortex</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control mg/kg</td>
<td>-0.59</td>
<td>31%</td>
<td>P = .045</td>
<td></td>
</tr>
<tr>
<td>Whole brain</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control mg/kg</td>
<td>-0.59</td>
<td>29%</td>
<td>P = .079</td>
<td></td>
</tr>
</tbody>
</table>

(Continued on page 29)
Benefit on Lowering Number of T1 Hypointensities
There was a 63% reduction in the mean number of larger (> 14 mm³ volume) new T1 hypointensities in patients treated continuously with 18 mg/kg of GNbAC1 monthly compared to the control group (P = .014).

Benefit on Magnetization Transfer Ratio
The MTR benefit of GNbAC1 18 mg/kg relative to the placebo group at 6 months remained stable versus the control group at 12 months, suggesting that GNbAC1 is beneficial in remyelination.

Safety and Tolerability
Safety and tolerability of GNbAC1 remained good, giving hope that GNbAC1 may be a safe treatment option to combat neurodegeneration. It seems clear that the benefit of GNbAC1 for patients with MS is mainly slowing of neurodegeneration and possible neuroprotection/remyelination, rather than a reduction of neuroinflammation. Higher doses of GNbAC1 should be tested in people with MS to see if an even more robust effect can be seen.

Summary
The 48-week results of CHANGE-MS are important because this trial is the first clinical demonstration of benefit with an anti-HERV antibody. There are ongoing proof-of-concept trials of GNbAC1 for type 1 diabetes mellitus, and the FDA has already granted an orphan drug designation for GNbAC1 for chronic inflammatory demyelinating polyneuropathy.

Got a minute for MS? Share @KantorNeurology


Daniel Kantor, MD, FAAN, FANA
President Emeritus of the Florida Society of Neurology
Founding President of the Medical Partnership 4 MS (MP4MS)
Program Director, Neurology Residency
Florida Atlantic University
Boca Raton, FL